Belzutifan - Generic Drug Details
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What are the generic sources for belzutifan and what is the scope of patent protection?
Belzutifan
is the generic ingredient in one branded drug marketed by Merck Sharp Dohme and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.Belzutifan has fifty-one patent family members in twenty-seven countries.
One supplier is listed for this compound.
Summary for belzutifan
| International Patents: | 51 |
| US Patents: | 2 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 23 |
| Clinical Trials: | 19 |
| Patent Applications: | 51 |
| What excipients (inactive ingredients) are in belzutifan? | belzutifan excipients list |
| DailyMed Link: | belzutifan at DailyMed |
Recent Clinical Trials for belzutifan
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Johns Hopkins Bloomberg School of Public Health | Phase 2 |
| Merck Sharp & Dohme LLC | Phase 1/Phase 2 |
| Merck Sharp & Dohme Corp. | Phase 1 |
US Patents and Regulatory Information for belzutifan
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merck Sharp Dohme | WELIREG | belzutifan | TABLET;ORAL | 215383-001 | Aug 13, 2021 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
| Merck Sharp Dohme | WELIREG | belzutifan | TABLET;ORAL | 215383-001 | Aug 13, 2021 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
| Merck Sharp Dohme | WELIREG | belzutifan | TABLET;ORAL | 215383-001 | Aug 13, 2021 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
| Merck Sharp Dohme | WELIREG | belzutifan | TABLET;ORAL | 215383-001 | Aug 13, 2021 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | See Plans and Pricing | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for belzutifan
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| World Intellectual Property Organization (WIPO) | 2015035223 | See Plans and Pricing | |
| Japan | 6746733 | See Plans and Pricing | |
| Croatia | P20191298 | See Plans and Pricing | |
| Peru | 20160434 | ETERES DE ARILO Y SUS USOS | See Plans and Pricing |
| Cuba | 20160030 | COMPUESTOS ÉTERES DE ARILO YÚTILES PARA TRATAR CANCER DE CÉLULA RENAL | See Plans and Pricing |
| >Country | >Patent Number | >Title | >Estimated Expiration |
